Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMole, Sara E-
dc.contributor.authorAnderson, Glenn-
dc.contributor.authorBand, Heather A-
dc.contributor.authorBerkovic, Samuel F-
dc.contributor.authorCooper, Jonathan D-
dc.contributor.authorKleine Holthaus, Sophia-Martha-
dc.contributor.authorMcKay, Tristan R-
dc.contributor.authorMedina, Diego L-
dc.contributor.authorRahim, Ahad A-
dc.contributor.authorSchulz, Angela-
dc.contributor.authorSmith, Alexander J-
dc.identifier.citationThe Lancet. Neurology 2019; 18(1): 107-116-
dc.description.abstractTreatment of the neuronal ceroid lipofuscinoses, also known as Batten disease, is at the start of a new era because of diagnostic and therapeutic advances relevant to this group of inherited neurodegenerative and life-limiting disorders that affect children. Diagnosis has improved with the use of comprehensive DNA-based tests that simultaneously screen for many genes. The identification of disease-causing mutations in 13 genes provides a basis for understanding the molecular mechanisms underlying neuronal ceroid lipofuscinoses, and for the development of targeted therapies. These targeted therapies include enzyme replacement therapies, gene therapies targeting the brain and the eye, cell therapies, and pharmacological drugs that could modulate defective molecular pathways. Such therapeutic developments have the potential to enable earlier diagnosis and better targeted therapeutic management. The first approved treatment is an intracerebroventricularly administered enzyme for neuronal ceroid lipofuscinosis type 2 disease that delays symptom progression. Efforts are underway to make similar progress for other forms of the disorder.-
dc.titleClinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis.-
dc.typeJournal Article-
dc.identifier.journaltitleThe Lancet. Neurology-
dc.identifier.affiliationNorthern Health, The University of Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Pediatrics, Washington University School of Medicine, St Louis, MO, USAen
dc.identifier.affiliationEpilepsy Research Centre, Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germanyen
dc.identifier.affiliationTelethon Institute of Genetics and Medicine, Naples, Italyen
dc.identifier.affiliationUCL Institute of Ophthalmology, University College London, London, UKen
dc.identifier.affiliationUCL School of Pharmacy, University College London, London, UKen
dc.identifier.affiliationCentre for Bioscience, Manchester Metropolitan University, Manchester, UKen
dc.identifier.affiliationBatten Disease Family Association, Farnborough, UKen
dc.identifier.affiliationDepartment of Histopathology, Great Ormond Street Hospital, London, UKen
dc.identifier.affiliationMedical Research Council Laboratory for Molecular Cell Biology and UCL Great Ormond Street Institute of Child Health, University College London, London, UKen
dc.type.austinJournal Article-
dc.type.austinReview-, Samuel F
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.cerifentitytypePublications- Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Feb 22, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.